Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Godavari Biorefineries receives patent from CNIPA
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
Subscribe To Our Newsletter & Stay Updated